August 15, 2008
Cutting Edge Information’s Research Shows Market for Breast Cancer Drugs to Top $40 Billion By 2012
The finding comes out of a new study released by market intelligence firm Cutting Edge Information. According to Cutting Edge Information's research, total oncology sales will grow by 56% between 2007 and 2012. 2007 sales amounted to approximately $18 billion.
The new report, "The Oncology Market Forecast to 2013," is a comprehensive study of more than 135 oncology drugs. The study takes a close look at the market for five major oncology indications, including colorectal, leukemia, lung, prostate and breast cancer. It also includes detailed forecasts for each drug, including forecasts for individual drug classes and top oncology drug manufacturers (http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp).
The market outlook for breast cancer treatments is bright indeed. Roche's and Genentech's blockbusters Avastin and Herceptin are currently undergoing clinical testing for cancer treatment. Meanwhile, several developmental drugs -- including Novartis' Gleevec -- are poised to take on the breast cancer market within the next couple of years. Gleevec is in Phase 3 trials for advanced breast cancer, and is expected to be a boon for Novartis on the order of several billion in annual sales.
"The market for breast cancer treatment is certainly on an upward trajectory," said Eric Bolesh, lead author of the study. "Several promising therapies are in the pipeline, and the options for treatment are ever-expanding -- which is good news for the industry and for patients."
The 420+ page study examines 17 monoclonal antibodies and more than 120 other drugs, and provides the following market analysis:
-- Individual Drug Profiles - Drug profiles include information about drugs' competitive, strategic and market growth positions. -- Oncology Indication Market Outlook - Detailed outlooks for the breast, colorectal, lung and prostate cancer and leukemia markets. -- Company Profiles - Oncology breakdowns for companies that either have established oncology franchises or exciting development pipelines for new cancer compounds.
CONTACT INFORMATION: Eric Bolesh Email Contact 919-433-0209
SOURCE: Cutting Edge Information